Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Conditions:   Squamous Cell Carcinoma, Head And Neck;   Squamous Cell Carcinoma Mouth;   Resectable Squamous Cell Carcinoma of Oral Cavity
Interventions:   Drug: Mocetinostat;   Biological: Durvalumab
Sponsors:   University Health Network, Toronto;   Mirati Therapeutics Inc.;   AstraZeneca
Not yet recruiting - verified December 2016

http://ift.tt/2gNEDDu